![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects
|
|
|
Reported by Jules Levin
61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting - October 29-November 2, 2010 - Boston, MA
Eric Lawitz1, Isabelle Gaultier2, Fred Poordad3, Daniel Cohen2, Rajeev Menon2, Lois M. Larsen2, Thomas Podsadecki2, Barry Bernstein2
1Alamo Medical Research, San Antonio, TX, United States; 2Global Pharmaceutical R & D, Abbott Laboratories, Abbott Park, IL, United States;
3Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, United States
![](../images/110810/110810-8/image002.gif)
![](../images/110810/110810-8/image004.gif)
![](../images/110810/110810-8/image006.gif)
![](../images/110810/110810-8/image008.gif)
![](../images/110810/110810-8/image010.gif)
![](../images/110810/110810-8/image012.gif)
![](../images/110810/110810-8/image014.gif)
![](../images/110810/110810-8/image016.gif)
![](../images/110810/110810-8/image018.gif)
![](../images/110810/110810-8/image020.gif)
![](../images/110810/110810-8/image022.gif)
![](../images/110810/110810-8/image024.gif)
![](../images/110810/110810-8/image026.gif)
![](../images/110810/110810-8/image028.gif)
![](../images/110810/110810-8/image030.gif)
![](../images/110810/110810-8/image032.gif)
![](../images/110810/110810-8/image034.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|